Table 2.

Clinical events in the cohort of subjects with resolved HBV infection treated with anti-CD20 monoclonal antibodies without antiviral prophylaxis

	Anti-HBc-positive individuals N = 28
Anti-CD20 therapy duration
Months of therapy	37.9 (25.6–48.5)
Number of cycles	6 (3–7)
HBV reactivation	0 (0%)
Need of corticosteroids pulses	1 (3.6%)
Infectious complications	3 (10.7%)
Permanent discontinuation of therapy	4 (14.3%)
Rituximab dose adjustment due to infections/side effects (N = 22)	3 (13.6%)

Variables are expressed as n (%) or median (IQR)